Shield Therapeutics plc
SHIEF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$91.55M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $91.55 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.02 |
| Beta | 1.72 |
| Outstanding Shares | 1,068,588,418 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -7.15 |
|---|---|
| PEG | 9.19 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$30.40 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 29, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Shield Therapeutics plc
61 employees
CEO: Anders Lundstrom
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/F...